2024
Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis
Chen L, Ren Z, Clark K, Lou C, Liu F, Cao Q, Manning A, Martin M, Luskin E, O'Donnell C, Azevedo C, Calabresi P, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Bilello M, Song J, Kaisey M, Sicotte N, Reich D, Solomon A, Ontaneda D, Sati P, Absinta M, Schindler M, Shinohara R, Cooperative T. Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis. Journal Of Neuroimaging 2024, 34: 750-757. PMID: 39410780, DOI: 10.1111/jon.13242.Peer-Reviewed Original ResearchParamagnetic rim lesionsArea under the curveRim lesionsMultiple sclerosisPrognosis of MSBiomarkers of chronic inflammationWhite matter lesionsMulticenter settingMulticenter studyMulticenter validationChronic inflammationBrain MRIClinical trialsIdentified lesionsMulticenterMS diagnosisLesionsParamagnetic rimAutomated segmentation methodMRIMRI biomarkersMulticenter datasetDiagnosisSclerosisTeam of trained raters
2023
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Alvarez E, Longbrake E, Rammohan K, Stankiewicz J, Hersh C. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Multiple Sclerosis And Related Disorders 2023, 79: 105009. PMID: 37783194, DOI: 10.1016/j.msard.2023.105009.Peer-Reviewed Original ResearchConceptsRisk of infectionCD20 therapySecondary hypogammaglobulinemiaMultiple sclerosisAnti-CD20 therapySerum immunoglobulin levelsB cell levelsDisease managementImmunoglobulin levelsSerious infectionsTherapy clinical trialsPotential complicationsClinical trialsHypogammaglobulinemiaPatientsTreatment approachesTherapyInfectionSclerosisRiskPossible mechanismMedicationsBest practice approachComplicationsPathogenesis
2022
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis And Related Disorders 2022, 68: 104143. PMID: 36031693, PMCID: PMC9772048, DOI: 10.1016/j.msard.2022.104143.Peer-Reviewed Original ResearchConceptsEfficacy of ocrelizumabMultiple sclerosisImmunologic biomarkersClinical trialsTransient B-cell depletionClinical multiple sclerosisCSF immune cellsEffects of ocrelizumabMS disease pathophysiologyNew brain lesionsOvert neurological symptomsB-cell depletionPlacebo-controlled studyPhase 4 studyLong-term outcomesPatient-reported outcomesPrimary progressive MSHumanized monoclonal antibodyFirst-degree relativesB cell biologySubtle cognitive impairmentEligible patientsImmune recoveryProgressive MSWeek 48
2017
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS
Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT. Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS. Multiple Sclerosis Journal 2017, 24: 1347-1355. PMID: 28766993, DOI: 10.1177/1352458517721357.Peer-Reviewed Original ResearchConceptsDisability Status ScaleStatus ScaleClinical practiceExpanded Disability Status ScaleMultiple sclerosis clinical trialsMultiple sclerosis clinical practiceCross-sectional comparisonCombiRx trialDisability scoresClinical trialsPilot cohortEDSSClinical monitoringPatient careClinical settingPatientsTrialsDisabilityFunctional systemsUseful measureScoringStandard measuresCohortCare
2013
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
Longbrake EE, Parks BJ, Cross AH. Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology And Neuroscience Reports 2013, 13: 390. PMID: 24027005, PMCID: PMC3967547, DOI: 10.1007/s11910-013-0390-z.Peer-Reviewed Original Research
2009
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Review Of Neurotherapeutics 2009, 9: 319-321. PMID: 19271940, DOI: 10.1586/14737175.9.3.319.Peer-Reviewed Original ResearchConceptsMultiple sclerosisRelapsing-remitting multiple sclerosisIL-12/ILPhase II clinical trialDose-ranging studyPhase I trialMechanism of actionRadiologic improvementAdvanced diseaseTherapy failsIL-23I trialIL-12/23IL-12Study inclusionPlacebo controlClinical trialsSubcutaneous injectionTreatment groupsAnimal modelsSclerosisPatientsAntibodiesTreatment effectsPhase II